Opioid Crisis Exposes Vulnerabilities in Suspicious Order Monitoring
August 20, 2018 | Shivani Patel
The American opioid crisis exposed gaps in the reporting systems designed to flag suspicious orders of pharmaceutical products classified as controlled substances. Pharmaceutical manufacturers are now facing increased scrutiny and need new approaches to monitor and report on irregular order patterns for controlled substances. This post discusses a new approach that provides visibility across pharmacy locations and wholesale distributors while weaving in additional demographic insights.